Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
CADL compared with URGN: revenue, margins and what each company keeps, and the suppliers and customers both name
CADL
Candel Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
URGN
UroGen Pharma Ltd.
Change
Mkt cap
Revenue
Revenue
vs
Compare
CADL
Candel Therapeutics, Inc.
vs
URGN
UroGen Pharma Ltd.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
CADL: latest quarter not drawable. URGN: latest quarter is a loss; flow not drawable.
Method
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
CADL, solid
URGN, dashed
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only CADL
0
None
Shared
0
No disclosed counterparties: CADL.
Only URGN
6
AGEN
Agenus
supplier
TEVA
Teva Pharmaceuticals Industries
supplier
—
Cenexi-Laboratories Thissen
unlisted
supplier
—
IconOVir Bio
unlisted
supplier
2 more · URGN chain
›
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
CADL
Candel Therapeutics, Inc.
Change
8.31
▼
−3.92%
· post 8.43
Mkt cap
$637.4M
Revenue
—
Revenue
—
URGN
UroGen Pharma Ltd.
Change
32.70
▼
−2.33%
· post 32.70
Closed
Oct 30 '26
Mkt cap
$1.6B
Revenue
$72M
Q2 FY26
Revenue
$110M
FY25
vs
Compare
Closed
Oct 30 '26
CADL
Candel Therapeutics, Inc.
vs
URGN
UroGen Pharma Ltd.
8.31
▼
−3.92%
post 8.43
Price
32.70
▼
−2.33%
post 32.70
$637.4M
Mkt cap
$1.6B
—
Revenue
$72M
Q2 FY26
—
Revenue
$110M
FY25
Change
Change
CADL
8.31
▼
−3.92%
vs
URGN
32.70
▼
−2.33%
Closed
Oct 30 '26